Wide Use of New HCV Drugs Prevents New Cases
by Michael Smith
North American Correspondent, MedPage Today
SEATTLE -- Unrestricted use of new direct-acting agents against hepatitis C (HCV) can markedly reduce the rate of new infections, a researcher said here.
That's based on analysis of what happened in the Netherlands among gay men with both HIV and HCV when unlimited access to the new, highly effective agents was rolled out in 2015, according to Bart Rijnders, MD, PhD, of Erasmus University Medical Center in Rotterdam, the Netherlands
Uptake of the drugs was substantial and the rate of new HCV infections was cut in half, Rijnders told reporters at the annual Conference on Retroviruses and Opportunistic Infections (CROI).
Continue reading....
Related
New hepatitis C infections among HIV-positive gay men drop by half after direct-acting antiviral roll-out in Netherlands
A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals for the treatment of hepatitis C, researchers have already seen a dramatic decline in acute hepatitis C virus (HCV) infections among one at-risk population, HIV-positive men who have sex with men.
These findings were reported on Thursday at the Conference on Retroviruses and Opportunistic Infections (CROI 2017) in Seattle, in a session that also included presentations on rising incidence of HCV infection among HIV-positive gay men in San Diego and predictions about eradication of HIV/HCV co-infection in France.
Continue reading...
Conference Coverage
Conference on Retroviruses and Opportunistic Infections (CROI)
February 13-16, 2017, Seattle WA
NATAP
No comments:
Post a Comment